Jakafi (ruxolitinib) for the treatment of moderate-risk or high-risk myelofibrosis
November 16, 2011, Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of moderate-risk or high-risk myelofibrosis (MF) patients, including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Incyte said, Jakafi is Janus-associated kinase A inhibitor of JAK1 and JAK2, JAK1 and JAK2 mediated by a variety of cytokines and growth factors in the signal transduction of these factors on hematopoiesis and immune function is significant. FDA approval for Jakafi order is based on two randomized phase 3 trial results. Patients receiving Jakafi, splenomegaly has been significantly improved. One of the trials, Jakafi MF can significantly improve symptoms (such as abdominal discomfort, pain under the left rib cage, early feeling bloating, night sweats, bone and muscle pain, and itching), and the majority of patients on placebo the above symptoms. Two studies the most commonly reported adverse reactions were thrombocytopenia and anemia, can be controlled and rarely led to treatment discontinuation Jakafi. The most common non-hematologic adverse reactions were bruising, dizziness and headache. Before starting Jakafi treatment complete blood count must be OK, and complete blood counts should be monitored as clinically indicated and used to guide therapy adjustments. In line with the clinical indications for platelet transfusions may be needed. Anemia patients may need a blood transfusion. For Jakafi patients should observe signs of infection (including herpes zoster) and promptly given anti-infection treatment. For most patients, the recommended starting dose is 15 or 20 mg, 2 times / d orally.
Jakafi (ruxolitinib) for the treatment of moderate-risk or high-risk myelofibrosis
ReplyDeleteNovember 16, 2011, Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of moderate-risk or high-risk myelofibrosis (MF) patients, including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Incyte said, Jakafi is Janus-associated kinase A inhibitor of JAK1 and JAK2, JAK1 and JAK2 mediated by a variety of cytokines and growth factors in the signal transduction of these factors on hematopoiesis and immune function is significant.
FDA approval for Jakafi order is based on two randomized phase 3 trial results. Patients receiving Jakafi, splenomegaly has been significantly improved. One of the trials, Jakafi MF can significantly improve symptoms (such as abdominal discomfort, pain under the left rib cage, early feeling bloating, night sweats, bone and muscle pain, and itching), and the majority of patients on placebo the above symptoms.
Two studies the most commonly reported adverse reactions were thrombocytopenia and anemia, can be controlled and rarely led to treatment discontinuation Jakafi. The most common non-hematologic adverse reactions were bruising, dizziness and headache.
Before starting Jakafi treatment complete blood count must be OK, and complete blood counts should be monitored as clinically indicated and used to guide therapy adjustments. In line with the clinical indications for platelet transfusions may be needed. Anemia patients may need a blood transfusion. For Jakafi patients should observe signs of infection (including herpes zoster) and promptly given anti-infection treatment.
For most patients, the recommended starting dose is 15 or 20 mg, 2 times / d orally.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Flavopiridol
Flavopiridol hydrochloride
SNS-032
AZD-5438
R547
PHA-848125
Dinaciclib
PHA-793887
CGP60474
CDK inhibitor II